BITS Pilani Hyderabad Turns Vaccine-Factory Wastewater Into Clean Water and Biogas

A research team at BITS Pilani's Hyderabad campus has developed a low-energy way to treat one of the pharmaceutical industry's most awkward waste streams — the effluent from vaccine and biopharmaceutical manufacturing — and turn it into reusable water and methane-rich biogas. Announced in late July 2026, the three-stage process is now being scaled up with Hyderabad-based vaccine maker Biological E. Limited, moving it from the laboratory toward industrial use.

The problem the team set out to solve is unglamorous but significant. Biopharmaceutical and vaccine plants generate wastewater loaded with the live microorganisms used in production, along with residual antibiotics and, worryingly, the genes that confer antimicrobial resistance. Treating that effluent conventionally is energy-hungry and chemical-intensive, and if it is done poorly, it can seed the environment with resistance genes — a slow-burning public-health risk. As India cements its position as one of the world's largest vaccine and biologics producers, the volume of this hard-to-treat wastewater only grows.

How the process works

The BITS Pilani Hyderabad system treats the effluent in three linked stages, designed to disinfect the water while recovering both clean water and energy — with markedly less heat and fewer chemicals than standard approaches.

The most distinctive element is the use of electric pulses to disinfect the wastewater. Rather than relying heavily on chlorine, ozone or high-temperature treatment, the process applies short, high-intensity electrical pulses that rupture the membranes of microorganisms — a technique that can neutralise complex biological contamination at low energy cost. Coupled with the other stages, this allows the system to safely knock down the microbial load, including antibiotic-resistant organisms, without the heavy energy penalty of thermal sterilisation.

Two valuable outputs emerge at the end. First, water clean enough to be reused within the plant — a meaningful benefit in water-stressed pharmaceutical hubs. Second, methane-rich biogas, recovered from the organic content of the waste, which can be burned as a clean fuel to offset the plant's own energy needs. In effect, a costly disposal problem is converted into two resources: recycled water and on-site energy.

Why the electric-pulse approach matters

The appeal of pulsed electrical disinfection is that it decouples effective sterilisation from high energy use. Biopharmaceutical effluent is difficult precisely because it is biologically active and chemically complex; brute-force thermal or chemical treatment works but is expensive and can create secondary waste. A low-energy electrical method that simultaneously permits water reuse and biogas recovery changes the economics — treatment stops being pure cost and starts paying part of its own way.

Recovering biogas also addresses the antimicrobial-resistance angle in a constructive way. By breaking down the organic load in a controlled system rather than discharging it, the process reduces the chance of resistance genes and live organisms escaping into rivers and soil, while capturing the resulting methane instead of letting it vent as a greenhouse gas.

From the lab to Biological E

So far, the technology has been demonstrated on biopharmaceutical fermentation wastewater under laboratory conditions. The important next step is industrial validation, and the team is working with Biological E. Limited — one of India's established vaccine and biologics manufacturers — to scale the system up and prove it on real plant effluent at production volumes.

That industry partnership is what separates this from a purely academic result. Scaling a wastewater process is notoriously difficult: what works on bench-scale samples must hold up against the variability, volume and round-the-clock operation of a real factory. Partnering with a major manufacturer from the outset gives the technology a realistic path to deployment and a demanding testbed.

The bigger picture

India's biopharma sector is a strategic national asset, supplying a large share of the world's vaccines. But its environmental footprint — particularly its wastewater and its role in the global antimicrobial-resistance challenge — is drawing increasing scrutiny. Solutions that let manufacturers clean their effluent affordably, recover water, and generate their own clean energy align neatly with both industrial competitiveness and sustainability goals.

If the BITS Pilani Hyderabad process performs at industrial scale, it points toward a circular model for pharmaceutical manufacturing, where the waste stream from making life-saving vaccines becomes a source of reusable water and renewable energy rather than a liability. It is a reminder that deep-tech innovation in India is not only about chips and rockets — sometimes it is about the quiet, essential engineering of what a factory does with its dirtiest water.

Sources

• United News of India — BITS Pilani Hyderabad develops sustainable technology to convert biopharma wastewater into reusable water & clean energy
• Deccan Chronicle — BITS Pilani team uses electric pulses to make wastewater reusable